By Fineline Cube Sanofi (NASDAQ: SNY) announced on 24 April 2026 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Cenrifki™ (tolebrutinib) for the treatment of secondary progressive multiple sclerosis (SPMS) in adults with no relapses in the past two years.
The recommendation—based on the Phase III HERCULES trial—positions tolebrutinib as a potential first-in-class brain-penetrant Bruton’s tyrosine kinase (BTK) inhibitor targeting smoldering neuroinflammation, a key driver of irreversible disability in progressive MS. A final EU marketing authorization decision is expected in the coming months.
Notably, this European advance contrasts with a U.S. regulatory setback: the FDA issued a Complete Response Letter (CRL) for the same indication in December 2025, though Sanofi has not disclosed specific deficiencies.
Clinical & Regulatory Profile
| Parameter | Detail |
|---|---|
| Drug | Cenrifki™ (tolebrutinib) – oral, brain-penetrant BTK inhibitor |
| Indication | Non-relapsing secondary progressive MS (SPMS) |
| Mechanism | Inhibits BTK in CNS-resident immune cells to suppress chronic neuroinflammation |
| Pivotal Trial | HERCULES Phase III – demonstrated significant delay in confirmed disability progression |
| EU Status | CHMP positive opinion (final EC decision pending) |
| U.S. Status | CRL received Dec 2025; resubmission timeline undisclosed |
| Unmet Need | No approved therapies specifically for non-relapsing SPMS; current options limited to symptom management |
Disease Context: The Burden of SPMS
- Progression Pattern: Continuous neurological decline independent of acute relapses
- Key Symptoms: Fatigue, cognitive impairment, gait dysfunction, loss of independence
- Patient Population: ~1 million SPMS patients globally; ~30% classified as non-relapsing
- Therapeutic Gap: Existing MS drugs primarily target relapsing forms; none halt progression in non-active SPMS
Strategic Implications for Sanofi
- Franchise Diversification: Success in SPMS would expand Sanofi’s neurology footprint beyond its blockbuster Dupixent and legacy MS drug Aubagio.
- BTK Platform Validation: Positive EU outcome de-risks the broader BTK inhibitor pipeline in autoimmune CNS disorders.
- Commercial Outlook: Even with U.S. delay, EU approval could generate €200–400 million peak annual sales by 2030, assuming premium pricing and rapid uptake in Germany, France, and Italy.
- Next Steps: Sanofi expected to engage FDA on CRL requirements while preparing European launch infrastructure.
Forward‑Looking Statements
This brief reflects current regulatory developments. Final EU approval, U.S. resubmission strategy, and commercial performance remain subject to agency decisions and market dynamics.-Fineline Info & Tech